New Book Empowers Dementia Care Partners to Navigate Challenges with Confidence and Calm
Grounded in Olson's extensive expertise and compassionate approach, 'Making Peace with Dementia' redefines how care partners approach their roles. The book highlights a pivotal yet surprising truth: mastering dementia care depends less on changing the individual with dementia and more on equipping care partners with practical strategies to manage and reduce stress.
The guide is divided into three core sections designed to empower care partners by exploring techniques for creating calm in their loved ones, cultivating a supportive environment, and finding personal clarity and balance. Olson's conversational and relatable style makes complex concepts accessible, helping readers sustain their energy, improve communication, and prepare for the future with pragmatic expectations.
'Families caring for loved ones with dementia often feel overwhelmed and lost,' says Olson. 'This book is my way of helping them discover that by learning practical strategies and rethinking their approach, they can create a more meaningful and peaceful experience for everyone involved.'
Ann Olson's professional background in treating neurological conditions, combined with her work as a dementia educator, coach, and senior living consultant, makes her uniquely positioned to offer this much-needed resource. Additionally, in 2022, Olson founded Sweet Basil Senior Care, an organization dedicated to supporting families navigating life with dementia.
The book is an invaluable resource for anyone seeking to enhance their caregiving skills, reduce tension, and rediscover joy in their relationships with those impacted by dementia.
'Making Peace with Dementia' (ISBN: 9781966074953 / 9781966074946) can be purchased through retailers worldwide, including Amazon and Barnes & Noble. The hardcover retails for $29.99, the paperback retails for $19.99, and the ebook retails for $2.99. Review copies and interviews with the author are available upon request.
For more information or to purchase the book, visit Amazon.
From the Back Cover:
Making Peace with Dementia was written for the dementia care partner who often is thrust into a difficult situation and struggles to provide care at the cost of their own health and happiness.
Author Ann Olson, an expert with decades of experience in dementia care, provides you with practical, easy-to-read guidance. Her book offers insight into the changes associated with dementia and equips you with strategies to side-step conflict, communicate effectively, and enhance safety and engagement.
Through real-life examples, Olson illustrates realistic and successful approaches for managing a variety of challenging situations. Numerous techniques are shared to help you prioritize your well-being and navigate dementia with greater calm, confidence and peace of mind.
About the Author
Ann Olson, OTR/L, is an occupational therapist specializing in neurological conditions, including dementia. Over her 25-year career, she has worked as a senior living consultant, educator, and dementia caregiver coach. Olson is also the founder of Sweet Basil Senior Care. She lives in Minneapolis, Minnesota, with her husband and dog, Violet.
About MindStir Media:
MindStir Media LLC is an award-winning book publisher. To learn more about publishing a book with MindStir Media, visit http://mindstirmedia.com or call 800-767-0531.
Michelle VanSledright
MindStir Media LLC
+1 800-767-0531
email us here
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
This Beaten-Down 8%-Yielding Dividend Stock Is Finally on the Road to Recovery
Key Points Medical Properties Trust's new tenants are paying steadily rising rental rates. The company has a couple more catalysts ahead. It offers a high-yielding dividend and substantial upside potential as its stock price recovers. These 10 stocks could mint the next wave of millionaires › Medical Properties Trust (NYSE: MPW) has endured a rough couple of years. The hospital-focused real estate investment trust (REIT) has faced the bankruptcies of its two largest tenants. Their financial troubles occurred during a period when interest rates surged, making it challenging to refinance debt as it matured. Shop Top Mortgage Rates Your Path to Homeownership A quicker path to financial freedom Personalized rates in minutes However, the healthcare REIT has gotten past this rough patch. As a result, it's now finally on the road to recovery, which was evident in its second-quarter results. That puts its roughly 8%-yielding dividend on a much more sustainable foundation, making the REIT an interesting option for those seeking income and upside potential. New tenants are starting to contribute Medical Properties Trust spent much of last year dealing with the bankruptcy of its former top tenant, Steward Health Care. The REIT was able to take back control of its real estate from Steward last September as part of the bankruptcy settlement. That allowed the hospital owner to transition the hospital operations to new tenants. It ultimately replaced Steward with five new tenants at 17 properties. Those new tenants started paying rent this year under leases that steadily escalate rental rates over the next two years. The group collectively paid only $3.4 million in rent during the first quarter. That amount increased to $11 million in the second quarter as rental rates continued to escalate steadily. This represented 96% of the rent it billed to these tenants (it didn't collect $500,000 in rent from two facilities due to some start-up issues). Three of its tenants are already paying the fully ramped-up cash rate. Rising rental income from these tenants, along with continued stability from most of its existing portfolio, enabled Medical Properties Trust to book a total of $240.4 million of revenue during the quarter. Meanwhile, the REIT reported $0.14 per share of normalized funds from operations (FFO) in the period. That easily supported its dividend payment of $0.08 per share. The recovery should continue Medical Properties Trust anticipates that rents from its new tenants will increase to $17 million in the third quarter. This number should continue rising. The REIT expects to reach the fully stabilized rate in October 2026, of around $160 million annualized (approximately $40 million per quarter). That drives its confidence that its annualized cash rent will exceed $1 billion by the end of next year. "In summary, our transitional portfolio is quickly ramping performance and rent payments as expected, and our other tenants from around the world are delivering consistent performance, driven by healthy volume and cost trends," stated Rosa Hooper, senior VP of operations, on the second-quarter call. She continued, "Put simply, MPT's portfolio is well positioned to continue to generate significant cash flow and create value for shareholders moving forward." More potential catalysts ahead The company has several potential additional catalysts that could enhance its ability to grow shareholder value in the future. One is the final resolution with its other bankrupt tenant (Prospect Medical Holding). In March, the bankruptcy court approved a settlement between the REIT, Prospect, and other parties that will allow the bankrupt healthcare company to sell its hospital operations and the related real estate owned by Medical Properties Trust. As those sales occur, the REIT will receive funds that it can use to repay debt or invest in new income-generating assets. Medical Properties Trust also continues to explore ways to grow earnings, reduce its cost of capital, and enhance its valuation. For example, it continues to own very valuable hospital real estate that it could monetize, potentially through joint venture transactions. Future moves could help unlock shareholder value by selling stakes in its properties at strong valuations and recycling the capital into new, higher-return investments. These moves could boost its share price and its ability to rebuild its dividend. Healthy total return potential Shares of Medical Properties Trust currently sit more than 80% below where they were in early 2022 before interest rates started rising, and its tenant issues began to worsen. That slump is why the company offers such a high dividend yield despite two deep cuts. With its tenant and balance sheet issues now in the rearview mirror, the REIT's reset dividend is safe and could start rising in the future as its rental income increases. That growth, along with future moves to unlock shareholder value, could help drive a recovery in Medical Properties Trust's stock price. This combination of income and upside potential makes it a potentially very attractive investment opportunity these days. Trump's Tariffs Could Create $1.5 Trillion AI Gold Rush The Motley Fool's analysts are tracking a massive shift in U.S. tech. Over $1.5 trillion is already flowing into infrastructure, AI, and advanced manufacturing… and the number keeps climbing. Following a major tariff policy shift, a new AI Gold Rush is taking shape, and we think . It builds the tech infrastructure that Apple, OpenAI, and others suddenly can't live without. We just released a full write-up on this under-the-radar stock — and why now might be the exact moment to move. Continue » *Stock Advisor returns as of August 4, 2025 Matt DiLallo has positions in Medical Properties Trust. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This Beaten-Down 8%-Yielding Dividend Stock Is Finally on the Road to Recovery was originally published by The Motley Fool
Yahoo
3 minutes ago
- Yahoo
Pfizer raises annual profit forecast
(Reuters) -U.S. drugmaker Pfizer raised its full-year profit forecast on Tuesday, boosted by robust demand for its heart disease drug, Vyndaqel, and some older treatments. The drugmaker now expects to earn $2.90 to $3.10 per share on an adjusted basis in 2025, compared with its previous expectations of $2.80 to $3.00 per share. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté
KB304 designed to deliver collagen and elastin to restore skin naturally Conference call to discuss results scheduled for Thursday, July 24, 2025 at 4:30pm ET PITTSBURGH, July 24, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ('Jeune'), a wholly owned subsidiary of Krystal Biotech, Inc. ('Krystal') (NASDAQ: KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally reverse the biology of aging skin, announced today positive safety and efficacy results, including significant improvements in key skin aesthetic attributes such as wrinkles and elasticity, in PEARL-2, a randomized, double-blind, placebo-controlled Phase 1 study evaluating KB304, for the treatment of wrinkles of the décolleté. Meaningful aesthetic improvements were reported following KB304 treatment with clear and statistically significant advantages over placebo as evaluated by both the investigator and subjects using the Global Aesthetic Improvement Scale (GAIS). GAIS assesses the overall aesthetic change in appearance as a result of a treatment. Subjects also reported increased satisfaction with the appearance of wrinkles, as measured by the Subject Satisfaction Questionnaire (SSQ). The SSQ is a tool to gather subject-reported outcomes providing valuable insights on the impact of treatment beyond clinical observations. Topline Efficacy Results A total of 19 subjects were enrolled, 12 were randomized to KB304 and seven to placebo. One subject dropped out before completing KB304 treatments. The remaining 18 subjects were assessed for aesthetic improvement out to three months following KB304 injections in the décolleté. The study investigator and subjects reported a clinically meaningful improvement in wrinkles one, two, and three months after treatment, as assessed by GAIS among KB304-treated subjects. Investigator Reported: At Least One-Point Improvement for Subjects Receiving: Subject Reported: At Least One-Point Improvement for Subjects Receiving: KB304 Placebo KB304 Placebo At Three Months 100% 28.6% 72.7% 14.3% At Two Months 100% 28.6% 90.9% 14.3% At One Month 100% 14.3% 72.7% 14.3% As assessed by SSQ, 81.8% of subjects receiving KB304 reported improved satisfaction with their wrinkles' appearance three months after treatment, compared to 14.3% of subjects receiving placebo. Improvements in subjects receiving KB304 were also seen across multiple additional skin attributes, as assessed by GAIS, including elasticity, crepiness, hydration, and radiance, for which the investigator reported that 100% of subjects demonstrated an improvement of at least 1 point in each of these attributes at one, two, and three months following treatment. 'We are very excited to share today's data update. We are pleased that both the investigator and subjects reported high rates of improvements across a variety of skin attributes when treated with KB304. We believe that KB304 has the potential to revolutionize the treatment of wrinkles and skin quality by directly addressing the underlying biology of aging skin. KB304 is a truly unique product candidate, which we think will address a massive gap in the market two ways…being the first product candidate to directly address elastin and by doing so in the décolleté where there are no injectable products approved. Consumers are yearning for a solution that delivers natural looking results, and KB304 has the potential to restore the skin to a more youthful appearance,' said Marc Forth, Chief Executive Officer of Jeune. The KB304 safety profile was consistent with prior clinical experience in KB301. Adverse events were mild-to-moderate and mostly reported after the first dose but substantially tapered off with subsequent doses. No severe or drug-related serious adverse events were reported. 'We are extremely excited by the promising data from the Pearl-2 study,' said Suma Krishnan, President of Research & Development at Krystal Biotech. 'We believe KB304 has the potential to be a first-in-class treatment to deliver collagen and elastin directly to the skin. This study is the first randomized, double-blind, placebo-controlled trial to investigate the potential combinatorial benefits of COL3 and elastin supplementation when produced by the body's own skin cells. On the basis of the strong results and broad improvements across multiple skin aesthetic attributes, we will be progressing KB304 into Phase 2 development for the treatment of wrinkles in the décolleté, a priority aesthetic site for which no FDA-approved injectables exist. We plan to prioritize the development of KB304 and will be meeting with the FDA in the coming months to enable initiation of the Phase 2 study.' Jeune has recently completed development and validation of a décolleté-specific photonumeric scale ('JDWS'). Jeune intends to submit the JDWS to the FDA and align on the Phase 2 study protocol in the second half of 2025 with the goal of initiating the Phase 2 study in the first half of 2026. Conference Call and Webcast Jeune and Krystal will host a conference call and webcast today, Thursday, July 24, 2025, at 4:30pm ET, to discuss the results of the PEARL-2 study, the KB304 clinical development program, Jeune's pipeline product candidates, and the strategic vision for Jeune. Investors and the general public can access the live webcast at: For those unable to listen to the live webcast, a replay will be available on the Investor's section of the Krystal website at About KB304 KB304 is an investigational aesthetic therapy employing Krystal's novel replication-defective, non-integrating HSV-1-based vector to deliver two copies of the gene encoding COL3 transgene and one copy of the gene encoding elastin to increase their levels in skin and address signs of skin aging associated with damage to the skin's extracellular matrix. KB304 is formulated as a solution for direct intradermal injection to aesthetic priority areas. About the PEARL-2 Study PEARL-2 is a Phase 1 Study of KB304, a replication-defective, non-integrating vector expressing human type III collagen (COL3) and elastin for the treatment of moderate to severe wrinkles of the décolleté. Details of the Phase 1 study can be found at under NCT identifier NCT06724900. About Jeune Aesthetics, Inc. Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal Biotech, Inc., is a biotechnology company leveraging a clinically validated gene-delivery platform to fundamentally address – and reverse – the biology of aging skin. For more information, please visit About Krystal Biotech, Inc. Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company's first commercial product, is the first-ever redosable gene therapy, and the first genetic medicine approved by the FDA and EMA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit and follow @KrystalBiotech on LinkedIn and X (formerly Twitter). Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for Krystal Biotech, Inc., or its wholly-owned subsidiary, Jeune Aesthetics, Inc., including statements about the clinical utility of KB304; KB304's ability to deliver collagen and elastin to restore the skin naturally to a more youthful appearance and potentially revolutionize the treatment of wrinkles and skin quality; KB304's potential to address a massive gap in the market; Krystal's and Jeune's plans to prioritize the development of KB304 and progress KB304 into a Phase 2 study for the treatment of wrinkles of the décolleté, including timing of meeting with the FDA and the goal of initiating the Phase 2 study in the first half of 2026; and other statements containing the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'predict,' 'project,' 'target,' 'potential,' 'likely,' 'will,' 'would,' 'could,' 'should,' 'continue,' and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: preliminary clinical data from a Phase 1 trial with a small sample size and limited follow-up may not predict results in later-stage studies; uncertainties associated with regulatory review of clinical trials, the availability or commercial potential of KB304, and such other important factors as are set forth under the caption 'Risk Factors' in Krystal's annual and quarterly reports on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Krystal's and Jeune's views as of the date of this press release. Krystal and Jeune anticipate that subsequent events and developments will cause their views to change. However, while Krystal and Jeune may elect to update these forward-looking statements at some point in the future, they specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing Krystal's and Jeune's views as of any date subsequent to the date of this press release. CONTACT Investors and Media: Stéphane Paquette, PhD Krystal Biotech spaquette@ Nishant Saxena Jeune Aesthetics nsaxena@ in to access your portfolio
